Entera Bio (NASDAQ:ENTX) is a clinical‐stage biotechnology company specializing in the development of orally administered peptide therapeutics. Leveraging a proprietary Intestinal Permeability Enhancement Technology (IPET), the company aims to transform peptide drugs—traditionally delivered by injection—into convenient once‐daily oral capsules. Headquartered in Rockville, Maryland, with research operations in Israel, Entera Bio focuses on addressing large‐market endocrinology and immunology indications by improving patient adherence and reducing healthcare costs associated with injectable therapies.
The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog designed to treat osteoporosis by stimulating bone formation. EB613 has completed multiple Phase 1 studies in healthy volunteers, demonstrating favorable safety and pharmacokinetic profiles. Entera Bio is also advancing EB612, another PTH‐based peptide tailored for hypoparathyroidism, with the goal of achieving stable regulation of calcium metabolism without the peaks and troughs seen with injections.
Beyond its endocrinology programs, Entera Bio is exploring the application of its IPET platform in immunology. A notable preclinical effort involves the oral delivery of cladribine, a small‐molecule immunomodulator currently used in the treatment of multiple sclerosis. This effort exemplifies the company’s strategic intent to expand its pipeline into additional therapeutic areas where improved oral bioavailability could enhance patient convenience and compliance.
Founded in 2006, Entera Bio is led by Ofer Spiegelman, President and Chief Executive Officer, whose background includes leadership roles at specialty pharmaceutical and biotechnology firms. The management team combines expertise in drug development, regulatory affairs and commercial strategy, supported by a board of directors with experience at leading global healthcare companies. As a Nasdaq‐listed entity (NASDAQ:ENTX), Entera Bio continues to build strategic partnerships and seek regulatory milestones to advance its oral peptide platform toward commercialization.
